Lonza has launched the TheraPRO CHO media system, a new cell-culture platform that simplifies processes and optimises productivity and protein quality when used with GS-CHO cell lines. The launch supports pharmaceutical and biotechnology companies manufacturing therapeutic proteins to further improve product quality while streamlining time to market.
The versatility and efficiency of antibody therapeutics continues to transform the healthcare industry. To meet growing demand for such therapies, biopharmaceutical manufacturers must optimise protein production and shorten time to market. However, protein production can be challenging, and unexpected issues that arise during scale-up and production can increase costs and delay delivery of life-changing therapies to patients.
To address these challenges, Lonza has developed the TheraPRO CHO media system. The chemically defined, animal-component free, two-part production system is easy to use and simplifies media preparation. It is fully scalable and is supported by technical experts with extensive experience in troubleshooting. The TheraPRO CHO media system delivers efficient performance, achieving high viable cell concentrations and more than 5g/L protein titer during a 15-day culture cycle. This represents more than double the protein titer that can be produced using existing solutions on the market.
Deirdre Raduns, Senior Global Product Manager, Bioscience, Lonza, commented: “Manufacturing high-quality biologics is a complex challenge, and doing so at scale and speed is even harder. The TheraPRO CHO media system leverages decades of GS-CHO cell culture expertise to address these challenges - offering notable performance through a simplified, two-part production system. With this launch, we are continuing our mission to help customers bring their life-changing therapies to market, faster.”
For more information on the TheraPRO CHO media system, please visit www.lonza.com/therapro.
